CALR and essential thrombocythemia: Antiplatelet therapies discussed earlier therefore pose a risk in myeloproliferative neoplasms, as patients with specific subgroup mutations, including CALR-positive-ET patients and patients with extremely high platelet counts, are at higher risk of bleeding when receiving low-dose aspirin [55,56,57,58,59].